Trial Profile
Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG-Nanodosing: the Path to Higher Sensitivity and Lower Toxicity Radiopharmaceuticals
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Nov 2015
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary)
- Indications Heart failure; Neuroendocrine tumours
- Focus Diagnostic use
- 26 Nov 2015 New trial record